GrayMatters Health

Company Overview

Snapshot

Founded in October 2018 by Rani Cohen, Oded Kraft, and Shai Attia, GrayMatters Health operates with 11–50 employees. The company has secured funding across 4 rounds from 8 investors. In March 2023, GrayMatters Health received an investment from the European Innovation Council (EIC) Fund.

Business overview

GrayMatters Health (GMH) develops digital self-neuromodulation therapeutics designed to help patients regain control over their emotion regulation for mental disorders. The company's core product, Prism, is a noninvasive adjunct therapeutic that utilizes neuroscience-based and brain-mechanism-specific biomarkers. GMH's initial product candidate, Prism for post-traumatic stress disorder (PTSD), is undergoing clinical investigation and has received FDA clearance. The company serves the healthcare industry, operating within the digital therapeutics, digital healthcare, and medical devices sectors.

Strategic signal

In May 2026, GrayMatters Health launched Prism Imagine, a generative digital brain biomarker platform for mental healthcare. This launch signals a significant advancement in the company's product offerings, moving towards more sophisticated and personalized digital therapeutics. For investors, this demonstrates GMH's continued innovation in leveraging digital biomarkers to enhance mental health treatment, potentially expanding its market reach and clinical impact.

Company Intelligence Q&A

What is GrayMatters Health's primary focus?

GrayMatters Health develops digital self-neuromodulation therapeutics for mental disorders, aiming to help patients improve emotion regulation through novel neuroscience-based and brain-mechanism-specific biomarkers.

When did GrayMatters Health receive FDA clearance for its PTSD product?

GrayMatters Health's first product, Prism for PTSD, was cleared by the FDA in March 2023.

Which investors participated in GrayMatters Health's January 2022 funding round?

In January 2022, GrayMatters Health closed a funding round with participation from.

What was a significant recent product launch for GrayMatters Health?

In May 2026, GrayMatters Health launched Prism Imagine, a generative platform utilizing digital brain biomarkers for mental healthcare.

What milestone did GrayMatters Health achieve in February 2026?

In February 2026, GrayMatters Health reached a clinical milestone of 10,000 Prism PTSD patient sessions, indicating significant adoption and use of its therapeutic platform.